CAI · Caris Life Sciences, Inc. · Insider Trading

Exercise of stock options before their expiration date.

The stock option is fully vested and exercisable.

The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Exercise of stock options before their expiration date.

The stock option is fully vested and exercisable.

The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.

Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.

Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.

The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The stock option is fully vested and exercisable.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

The stock option is fully vested and exercisable.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The stock option is fully vested and exercisable.

The stock option is fully vested and exercisable.